242 related articles for article (PubMed ID: 30029613)
1. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
Arthritis Res Ther; 2018 Jul; 20(1):151. PubMed ID: 30029613
[TBL] [Abstract][Full Text] [Related]
2. Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study.
Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
Mod Rheumatol; 2021 Jan; 31(1):42-52. PubMed ID: 31903822
[TBL] [Abstract][Full Text] [Related]
3. Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study): a multicenter, post-marketing, non-interventional, observational trial.
Athanassiou P; Katsimbri P; Bounas A; Gazi S; Sarikoudis T; Syrigou V; Boumpas D;
Clin Rheumatol; 2024 May; 43(5):1469-1478. PubMed ID: 38472527
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
Ogata A; Tanimura K; Sugimoto T; Inoue H; Urata Y; Matsubara T; Kondo M; Ueki Y; Iwahashi M; Tohma S; Ohta S; Saeki Y; Tanaka T;
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):344-54. PubMed ID: 23983039
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
[TBL] [Abstract][Full Text] [Related]
7. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial.
Sanmarti R; Veale DJ; Martin-Mola E; Escudero-Contreras A; González C; Ercole L; Alonso R; Fonseca JE;
Arthritis Rheumatol; 2019 Oct; 71(10):1616-1625. PubMed ID: 31087542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
[No Abstract] [Full Text] [Related]
10. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Choy E; Caporali R; Xavier R; Fautrel B; Sanmarti R; Bao M; Devenport J; Pethö-Schramm A
Rheumatology (Oxford); 2019 Jun; 58(6):1056-1064. PubMed ID: 30649524
[TBL] [Abstract][Full Text] [Related]
11. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N; Fukui S; Umeda M; Nishino A; Nakashima Y; Suzuki T; Horai Y; Nonaka F; Okada A; Koga T; Kawashiri SY; Fujikawa K; Aramaki T; Ichinose K; Hirai Y; Tamai M; Nakamura H; Terada K; Nakashima M; Mizokami A; Origuchi T; Eguchi K; Ueki Y; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):662-6. PubMed ID: 26708444
[TBL] [Abstract][Full Text] [Related]
13. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
McLaughlin M; Östör A
Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
16. Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study.
Behrens F; Burmester GR; Hofmann MW; Aringer M; Kellner H; Liebhaber A; Wassenberg S; Peters MA; Zortel M; Amberger C
Clin Exp Rheumatol; 2023 Jul; 41(7):1463-1472. PubMed ID: 36622132
[TBL] [Abstract][Full Text] [Related]
17. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
Takeuchi T; Nakajima R; Komatsu S; Yamazaki K; Nakamura T; Agata N; Igarashi A; Tango T; Tanaka Y
Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study).
Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Lu P; Rowell L; Bao M; Mysler EF
Ann Rheum Dis; 2014 Jan; 73(1):69-74. PubMed ID: 23904473
[TBL] [Abstract][Full Text] [Related]
20. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
